The commencement of share trading on the SIX Swiss Exchange as an independent entity is being celebrated by Sandoz, the global leader in generic and biosimilar medicines. This event signifies the successful completion of a 100% spin-off from its former parent company, Novartis, and the incorporation of Sandoz Group AG shares into key Swiss market indices.
The newly established company has been listed on several Swiss indices, including the Swiss Performance Index (SPI®) and the Swiss Leader Index (SLI®), along with the commencement of trading in Sandoz ADRs (American Depositary Receipts) on the US OTCQX®.
Sandoz’s core Purpose, rooted in its scientific heritage, remains unaltered. Since its inception in 1886 as Kern & Sandoz, the company has consistently excelled in making quality medicines accessible to a wider audience, epitomized by milestones such as the development of Calcium Sandoz in 1929 and the introduction of the world’s first biosimilar in 2006.
Under its new status as an independent company, Sandoz is fully equipped to execute its purpose-driven strategy, concentrating on securing sustainable leadership within the evolving generics and biosimilars industry. Six strategic levers have been outlined to drive long-term value, encompassing market fundamentals, leadership and scale, multiple growth drivers, margin enhancement, accelerated cash generation, and the presentation of a compelling sustainability narrative.
The generics and biosimilars sector, accounting for a substantial share of medicines used globally by volume and cost, is poised for consistent growth over the next decade. Sandoz’s mission to enhance access for patients and its substantial global impact, including annual savings exceeding USD 17 billion in Europe and the US, mirror its dedication to the industry’s essential medicines.
In Canada, Sandoz is now better equipped to serve its eight million patients, aligning with their commitment to healthcare innovation and support for a sustainable healthcare system.
Sandoz’s emergence as an independent entity ushers in a new era for the company. While the core purpose of pioneering access for patients remains constant, the transition empowers Sandoz to further its mission in the generics and biosimilars industry.